Evidence map›Paper›PMID 39406880›Full record

ArticleCommunications medicine2024

Evaluation of an engineered vascular graft exhibiting somatic growth in lambs to model repair of absent pulmonary artery branch.

Zeeshan H Syedain, Matthew Lahti, Gurumurthy Hiremath, James Berry, John P Carney, Jill Schappa Faustich, Tate Shannon, Andrea Rivera, Hadi Wiputra, Zhitian Shi and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. NovoMemHistology and histopathology · 2026
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Zeeshan H SyedainDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, MN, USA.ORCID http://orcid.org/0000-0001-5536-6542
Matthew LahtiDepartment of Surgery & Experimental Surgical Services, University of Minnesota, Minneapolis, MN, USA.
Gurumurthy HiremathDepartment of Pediatrics & Masonic Children's Hospital, University of Minnesota, Minneapolis, MN, USA.ORCID http://orcid.org/0000-0001-6686-896X
James BerryDepartment of Surgery & Experimental Surgical Services, University of Minnesota, Minneapolis, MN, USA.
John P CarneyDepartment of Surgery & Experimental Surgical Services, University of Minnesota, Minneapolis, MN, USA.ORCID http://orcid.org/0000-0002-2090-7764
Jill Schappa FaustichDepartment of Surgery & Experimental Surgical Services, University of Minnesota, Minneapolis, MN, USA.
Tate ShannonDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, MN, USA.
Andrea RiveraDepartment of Biomedical Engineering, Florida International University, Miami, FL, USA.ORCID http://orcid.org/0000-0002-9830-762X
Hadi WiputraDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, MN, USA.
Zhitian ShiDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, MN, USA.ORCID http://orcid.org/0009-0005-0237-9741
Richard BiancoDepartment of Surgery & Experimental Surgical Services, University of Minnesota, Minneapolis, MN, USA.
Robroy MacIverChildren's Hospitals and Clinics of Minnesota, Minneapolis, MN, USA.
John E MayerBoston Children's Hospital and Department of Thoracic Surgery, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5849-2971
Robert T TranquilloDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, MN, USA. tranquillo@umn.edu.

Funding

U.S. Department of Defense (United States Department of Defense) W81XWH-22-1-0489
6 · The paper itself

Abstract

backgroundGrowth is the holy grail of tissue implants in pediatrics. No vascular graft currently in use for surgical repairs of congenital heart defects has somatic growth capacity.

methodsBiologically-engineered grafts (6 mm) grown from donor ovine fibroblasts in a sacrificial fibrin gel were implanted into the left pulmonary branch of 3-month old lambs for 3, 6, and 18 months. A control group of Propaten® PTFE grafts was implanted for 6 months.

resultsThe engineered grafts exhibit extensive site-appropriate recellularization after only 3 months and near-normal increase of diameter from the preimplant value of 6 mm to 12.9 mm and also a doubling of length from 6.0 mm to 13.0 mm at 6 months (n = 3) associated with apparent somatic graft growth (collagen content increase of 265% over 18-month, n = 2), along with excellent hemodynamics and no calcification, in contrast to the Propaten® grafts. The left-right flow distribution is nearly 50-50 for the engineered grafts at 6 months (n = 3) compared to about 20-80 for the Propaten® grafts (n = 3), which have less than one-half the diameter, a 6-fold higher pressure gradient, and stunted vascular development downstream of the graft. The engineered grafts exhibit a stable diameter over months 12-18 when the lambs become adult sheep (n = 2).

conclusionsThis study supports the use of these regenerative grafts with somatic growth capacity for clinical trial in patients born with a unilateral absent pulmonary artery branch, and it shows their potential for improving development of the downstream pulmonary vasculature.

Identifiers

PMID39406880
PMCPMC11480500

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.